* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Receptor Antagonists Competitive Antagonist • drug acts at the
Pharmacokinetics wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of TRPV1 antagonists wikipedia , lookup
Drug design wikipedia , lookup
Drug interaction wikipedia , lookup
CCR5 receptor antagonist wikipedia , lookup
NMDA receptor wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
5-HT3 antagonist wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Toxicodynamics wikipedia , lookup
5-HT2C receptor agonist wikipedia , lookup
Psychopharmacology wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Neuropharmacology wikipedia , lookup
Receptor Antagonists Competitive Antagonist • drug acts at the same receptor and competes with the agonist for the active site (or orthosteric binding site) Non-Competitive Antagonist • binding at an allosteric binding site o may impact the affinity or efficacy of agonist binding Competitive Antagonist Ø binds to the orthosteric site Ø copetitive antagonist occupes site but does not generate a stimulus o No stimulus à no ion flux à no response Reversible • Only one drug can be at a receptor at any one time. • At any given concentration of antagonist, there will be fewer receptors available for binding of the agonist ∴ fewer agonist-receptor complexes ∴ reduced response • If we increase [agonist], they can out-compete the antagonist o Antagonist effect is reversible (or summountable) by ↑ [agonist] • In realtiy, while some antagonists are reversible, they can take some time to be reversed o ∴ effects of an antagonist usually lasts longer than the effects of an agonist Irreversible • Antagonist has a stronger bond (covalent) to the receptor compared to the agonist • Fewer receptors available to bind to and ↑ [agonist] does not allow agonist to bind thus does not increase response (insummountale or irreversible) Antagonists alter the action of an agonist actng t the same receptor à alter the position or shape of the log CR curve Learning Objectives describe how Occupation Theory-based receptor models have evolved and shaped our understanding of agonist actions explain the concepts of efficacy, partial agonists, spare receptors and inverse agonists explain the effects of competitive receptor antagonists on agonist CR curves Efficacy Clinical efficacy: “the power to produce an effect” • e.g. does it alter blood pressure, etc. cf: clinical efficacy Ability of a drug, once bound, to activate the receptor to cause a response Receptor occupancy vs Response Occupation Theory Models Clark’s Model • response determined by the proportion of receptors occupied by the drug !" o i.e response = " $%$&' • maximal response occurs when all receptors are occupied o i.e. Emax ∝ [R]total à response depends on number of receptors in the tissue o relationship between occupancy & response is direct and linear Implies: • maximum response is a property of the tissue • all agonists will have the same maximum response BUT: The NeuroMuscular Junction (NMJ) has ~ 30,000,000 AcetyCholine (Ach) receptors - activation of only 40,000 required for Action Potential (twitch of muscle fibre) o some receptors are inactivated at times. If we only had exactly how much we need, as soon as the inactivation process begins, we will have some drastic conseuqences in the tissue - receptor reserve in tissues (approx. 100-1000X what is required) Spare Receptors ..in excess of those needed to produce a maximum response • If a full agonist requires occupation of only 5% of the available receptors in order to produce a maximal response, then 95% of receptors are spare receptors for that agonist. ⇒ there is a receptor reserve of 95% for that agonist. Drugs acting on the same receptor but producing different maximum responses. à not all drugs are equal Modification to Clark’s Model Ariens (1954) and Stephenson (1956): Response: [DR] / [R]total ‘intrinsic efficacy’ Full Agonist Partial Agonist • some agonists can produce a maximal response when occupying fewer than 100% of receptors à “full” agonist • some agonists need to occupy all (or a greater proportion of) receptors in order to produce a maximal response à “partial” agonist Further Modifications RF Furchgott: • “Efficacy” is determined by both the intrinsic efficacy of the drug (ε) and the receptor density (total amount of receptors [R]total) T Kenakin: • Mathematical modelling.... Current Thinking maximum response of a tissue to a drug is determined by: [R]total & coupling between receptor & response à(tissue characteristics) AND Efficacy à(drug characteristic) • in a tissue with a lot of spare receptors, a partial agonist may appear as a full-agonist Studying Agonists ConcentrationResponse Curves We can plot data as: • absolute response (tension) in grams • response as a % of maximum Partial Agonists Partial Agonists: ü have affinity ü have efficacy, but LOWER than that of a full agonist o unable to activate the receptor to the full extent Efficacy ≠ Occupancy Efficacy ≠ Potency Efficacy refers to the ability of the drug, once bound, to activate the receptor whereas potency refers to how much of the drug is required to produce a particular effect. Efficacy is measured by Emax Potency is measure by EC50 Efficacy: L=N > M Potency: L>M>N What determines efficacy? different conformational states of R* (activated receptor) ü determined by ligand ü can influence signalling (e.g. GPCRs) Spare Receptors and Partial Agonists In a tissue, where there is no spare receptors, a partial agonist cannot cause a maximal response even if it is bound to all receptors. If an agonist is a partial agonist, but the tissue has lots of reserve (spare) receptors, a partial agonist may appear to be a full agonist because it can cause a maximal response Selectivity • most drugs can interact with >1 receptor to produce multiple effects • effects determined by affinity and efficacy at each receptor if we show that different concentrations cause different responses, we can show some selectivity for the drug…at low concentrations, we can have one effect but not another…as concentration increases, we get more responses Studying Antagonists Start of with a known agonist. When we add antagonist, the curve should shift to the right. Competitive Reversible Antagonists • competes with agonist for SAME site on receptor o the one that gets to the receptor most is the one that has the highest concentration • surmountable – ie ↑ [agonist] can ‘overcome’ • reversible on washing Effect on agonist CR curve? ü ü ü ü Competitive Irreversible Antagonists Parallel shift to the right Same Emax Same efficacy ↑ EC50 (reduced potency) ∴ ↓pEC50 • dissociates slowly from the binding site • essentially insurmountable • essentially irreversible o reducing number of receptors (inactiviating them so they are not available to the agonist). o if we have enough antagonist, we will get no response. Effect on agonist CR curve? ü ↓ Emax with increasing [antagonist] e.g. PBZ (phenoxybenzamine) • interacts with a range of receptors o ACh receptors, histamine receptors, α-adrenergic receptors o binds covalently to all these receptors